Gritstone Bio - Stock Price History | GRTS

Historical daily share price chart and data for Gritstone Bio since 2021 adjusted for splits. The latest closing stock price for Gritstone Bio as of September 24, 2021 is 11.35.
  • The all-time high Gritstone Bio stock closing price was 31.10 on December 06, 2018.
  • The Gritstone Bio 52-week high stock price is 35.20, which is 210.1% above the current share price.
  • The Gritstone Bio 52-week low stock price is 2.54, which is 77.6% below the current share price.
  • The average Gritstone Bio stock price for the last 52 weeks is 8.62.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Gritstone Bio Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 5.4383 8.1300 11.3000 2.5700 3.9400 -56.08%
2019 10.7768 16.2900 18.9600 7.0700 8.9700 -41.94%
2018 19.0064 14.2400 31.1000 11.6100 15.4500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.584B $0.004B
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71